Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Immunol., 24 November 2025

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1741271

Correction: Receptor tyrosine kinase inhibitor sunitinib as novel immunotherapy to inhibit myeloid-derived suppressor cells for treatment of endometriosis

This article is a correction to:

  1. Receptor Tyrosine Kinase Inhibitor Sunitinib as Novel Immunotherapy to Inhibit Myeloid-Derived Suppressor Cells for Treatment of Endometriosis

    1. Read original article
Ying HeYing He1Sze Wan HungSze Wan Hung1Bo LiangBo Liang1Ruizhe ZhangRuizhe Zhang1Yating GaoYating Gao1Ching Yan ChuChing Yan Chu1Tao ZhangTao Zhang1Hui XuHui Xu1Jacqueline Pui Wah ChungJacqueline Pui Wah Chung1Chi Chiu Wang,,,*Chi Chiu Wang1,2,3,4*
  • 1Department of Obstetrics & Gynaecology, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China
  • 2Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China
  • 3School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China
  • 4Chinese University of Hong Kong–Sichuan University Joint Laboratory in Reproductive Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China

A Correction on
Receptor tyrosine kinase inhibitor sunitinib as novel immunotherapy to inhibit myeloid-derived suppressor cells for treatment of endometriosis

By He Y, Hung SW, Liang B, Zhang R, Gao Y, Chu CY, Zhang T, Xu H, Chung JPW and Wang CC (2021). Front. Immunol. 12:641206. doi: 10.3389/fimmu.2021.641206

An incorrect Funding statement was provided. The correct Funding statement reads:

“This research was supported by The Hong Kong Obstetrical & Gynaecological Trust Fund 2019 from Hong Kong Society of Obstericians and Gynaecologists; Academic Equipment Grant (3029876); and Direct Grant (2017.044) from The Chinese University of Hong Kong.”

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: endometriosis, myeloid-derived suppressor cells, Sunitinib, immunosuppression, gene expressions

Citation: He Y, Hung SW, Liang B, Zhang R, Gao Y, Chu CY, Zhang T, Xu H, Chung JPW and Wang CC (2025) Correction: Receptor tyrosine kinase inhibitor sunitinib as novel immunotherapy to inhibit myeloid-derived suppressor cells for treatment of endometriosis. Front. Immunol. 16:1741271. doi: 10.3389/fimmu.2025.1741271

Received: 07 November 2025; Accepted: 12 November 2025;
Published: 24 November 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 He, Hung, Liang, Zhang, Gao, Chu, Zhang, Xu, Chung and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Chi Chiu Wang, Y2N3YW5nQGN1aGsuZWR1Lmhr

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.